| BARBARA GREEN | PRIME PEOPLE
showed that it has a very quick effect on the skin ® especially to the deeper layers of the skin ® making it appropriate for use on deeper lines and wrinkles. 'We've been very excited about the
data gathered, and happy to partner with Avon to advance the science around this product.'
Supporting dermatology Indeed, based on Nobel Prize-winning research, with A-F33, NeoStrata were able to identify that the molecule could even be considered a new 'gold standard' skincare ingredient. In the 'normal' ageing process, collagen
production progressively slows, and fine lines and thin skin gradually become apparent. Faulty enzyme modification in the cells that produce collagen can block the production of collagen in normal cells. A-F33 intercepts this mechanism, allowing more functional collagen to form ® as well as stimulating its production ® to provide improvements to both fine and deep wrinkles. 'Through our collaboration with Avon
scientists,' Barbara says, 'we discofvered the benefits of the A-F33 molecule and we are thrilled about the effects this
discovery has on the skin, and what this compound could mean for the future of the anti-ageing industry.' NeoStrata has developed and
marketed a comprehensive range of skincare products, with advanced cosmetic products, to meet the needs of every skin type and on a worldwide basis. 'As a company, when we're selling in
collaboration with dermatologists, we always look for treatments that would be complementary to what they're doing in the office. There are patients that love injectable therapies, but not all injectables manage all skincare concerns, such as texture for instance, so this is a perfect example of a partnership of a topical combined with all other modalities available to the dermatologist.' And in this regard, Barbara believes
that the new technology will be well received within the market as a result of its mechanism of action and resulting benefits.
The future of anti-ageing In just 20 years, the anti-ageing and aesthetic industry has changed dramatically, especially when one considers the development of topical
therapies. In 1988, for example, Dr John J. Vorhees published the first double-blind study of the effect of Retin-A (tretinoin) on photodamaged skin, concluding that 100% of participants showed an improvement in the appearance of skin texture, wrinkles and discolouration after 16 weeks. And now, following the development
of laser and intense pulsed light (IPL) therapies, the rise of injectables and invasive procedures, skincare regimens remain an essential treatment protocol for the dermatologist. As these treatment methologies
continually develop, Barbara sees trends in skincare moving to the harnessing of genetic and stem cell technologies, through which our own collagen can be stimulated, as well as elastin and fibrillin. It is for this reason that Barbara and the
team at NeoStrata are excited about the continuing partnership with Avon, and look forward to seeing how this new product development will be received by the aesthetic and anti-ageing market.
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84